ArticleClinical and translational gastroenterology2026
Automated Eosinophil Quantification Using Deep Learning to Predict Therapy Escalation in Pediatric Ulcerative Colitis.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionEmerging evidence implicates eosinophils as important modulators of disease activity and therapeutic response in ulcerative colitis (UC). Automated image analysis provides a scalable and reproducible approach to their evaluation, overcoming the limitations of manual quantification.
methodsWe developed a U-Net-based deep learning model to automate eosinophil detection, using whole-slide images from 2 pediatric sites. Pathologist-annotated 500 × 500-pixel patches served as training data; model performance was evaluated using area under the receiver operator curve (AUROC), precision, recall, and F1 score and benchmarked against SAU-Net, YOLO-v8, and HoVer-Next. The validated algorithm was applied to rectal biopsies from treatment-naïve children with moderate-to-severe UC in the PROTECT inception cohort (n = 221). Eosinophil metrics (density in cells/mm 2 and peak high-power field counts) were analyzed for associations with baseline clinical, histologic, and endoscopic features and 1-year clinical outcomes including anti-tumor necrosis factor α (TNFα) escalation and corticosteroid-free clinical remission. Predictive models were evaluated with logistic regression and machine learning approaches using 5-fold cross-validation.
resultsThe segmentation model achieved high accuracy (test AUROC = 0.94, F1 score = 0.86) and strong concordance with expert counts (ρ = 0.87-0.89). Higher eosinophil density and counts correlated with basal lymphoid aggregates ( P < 0.001) and predicted week 4 and corticosteroid-free remission ( P = 0.03 and P = 0.01, respectively). Lower eosinophil counts predicted escalation to anti-TNFα therapy ( P = 0.04). Incorporation of eosinophil metrics into Predicting Response to Standardized Pediatric Colitis Therapy (PROTECT) clinical models maintained predictive accuracy for anti-TNFα escalation (AUROC = 0.79; accuracy = 0.76). DISCUSSION: Deep learning-based eosinophil quantification has the potential to transform pediatric UC care by serving as a reproducible biomarker that informs risk stratification and to guide therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.